Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Timolol

Timolol

Timolol is a non-selective beta-adrenergic receptor antagonist used to treat various conditions, including glaucoma, hypertension, and angina pectoris.
It works by blocking the effects of the neurotransmitter norepinephrine, which can help lower intraocular pressure and blood pressure.
Timolol is available in several formulations, including eye drops, ointments, and oral tablets.
Researchers can optimize their Timolol studies using PubCompare.ai, an AI-driven tool that helps identify the most relevant protocols from scientific literature, preprints, and patents.
With its innovative comparison features, PubCompare.ai can assist in selecting the best protocols and products to enhance the reproducibility and accuracy of Timolol research, streamlining the research process and taking Timolol optimization to new heights.

Most cited protocols related to «Timolol»

1
Observational Study of PF Tafluprost/Timolol FC
Cited 4 times
This was a 6-month, observational, multicenter, European, prospective clinical study. In line with European Medicines Agency (EMA) requirements, the study was registered under the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP®) European Union electronic Register of Post-Authorisation Studies (EU PAS Register) (EU PAS register number EUPAS22204). The study complied with the principles of the Declaration of Helsinki. All patients included were required to provide written informed consent prior to their enrollment. The study protocol was approved by the institutional review board (IRB) or independent ethics committee (IEC) at each center/institution. The study centers/institutions are listed in the Acknowledgments alongside the relevant principal investigator.
Data were prospectively collected during routine visits, between 10 April 2017 and 9 January 2019, at 66 ophthalmology clinics in Austria, Denmark, Hungary, Ireland, Italy, Latvia, Netherlands, Norway, Russia, Spain, Sweden, and the UK. For patients, attendance was mandatory only for the baseline and month 6 study visits. However, data were recorded during interim study visits at week 4 and week 12 for participants who chose to attend these visits.
Baseline measures were recorded under topical PGA or beta-receptor blocker medication within 7 days prior to therapy change to PF tafluprost/timolol FC. Variables were documented for each eye separately at baseline and at study visits following initiation of PF tafluprost/timolol FC treatment. Where data on both eyes were available, the eye with the higher baseline IOP value was selected for analysis (study eye).
Oddone F., Tanga L., Kóthy P, & Holló G. (2020). Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study. Advances in Therapy, 37(4), 1436-1451.
Publication 2020
Adrenergic beta-Antagonists Ethics Committees, Research Europeans Institutional Ethics Committees Patients Pharmaceutical Preparations tafluprost Timolol
2
Efficacy of Preservative-Free Glaucoma Therapy
Cited 3 times
Male/female adult patients (aged ≥ 18 years) with a diagnosis of OAG or OHT were included in the study. Participants had to be on a PGA or a beta-receptor blocker monotherapy at time of inclusion. They had to have medically recorded insufficient IOP control or poor tolerance on the beta-receptor blocker or PGA monotherapy prior to enrollment, which necessitated the use of a combination therapy, and the patients had to be considered likely to benefit from PF drops formulation, according to the judgement of the investigator ophthalmologist. It was possible for the investigator to indicate more than one reason for patient selection in the case report form. The category of reasons for indicating PF tafluprost/timolol FC comprised insufficient IOP control or progression of glaucoma on the current monotherapy, conversion of OHT to OAG, poor local tolerance of the current topical medication, insufficient adherence to the medication used, or “other reasons”.
The inclusion criteria required that the participants had not undergone ophthalmic surgery within 6 months prior to the study period and had never received previous PF tafluprost/timolol FC treatment. Patients who were pregnant or breastfeeding at the screening visit and those with any contraindication against tafluprost or timolol treatment according to the approved licensed indication and the summary of product characteristics were not allowed to enter the study.
Oddone F., Tanga L., Kóthy P, & Holló G. (2020). Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study. Advances in Therapy, 37(4), 1436-1451.
Publication 2020
Adrenergic beta-Antagonists Adult Combined Modality Therapy Diagnosis Disease Progression Glaucoma Immune Tolerance Males Ophthalmologic Surgical Procedures Ophthalmologists Patients tafluprost Timolol Woman
3
Purification of Timolol-Bound GPCR Receptors
Cited 3 times
Frozen membranes were thawed on ice and NaCl, MgCl2, and GTPγS were added to reach final concentrations of 300 mM, 1 mM, and 10 μM, respectively. Timolol was then added to a final concentration of 1 μM and the membranes were incubated for 10 minutes on ice. Receptors were solubilized for 1 hour at 4 °C in the presence of 1% dodecylmaltoside (DDM) and 0.1% cholesterol hemisuccinate (CHS). Following centrifugation for 30 minutes at 25,000g, the supernatant was applied to Ni-NTA agarose. The column was slowly washed with 20 column volumes of 20 mM HEPES, pH 8.0, 300 mM NaCl, 0.1% DDM, 0.01% CHS to remove bound timolol. Receptor was eluted in the same buffer plus 200 mM imidazole and concentrated using an Amicon 30 kDa-cutoff spin concentrator for addition to the rHDL reconstitution mixture.
DeVree B.T., Mahoney J.P., Vélez-Ruiz G.A., Rasmussen S.G., Kuszak A.J., Edwald E., Fung J.J., Manglik A., Masureel M., Du Y., Matt R.A., Pardon E., Steyaert J., Kobilka B.K, & Sunahara R.K. (2016). Allosteric coupling from G protein to the agonist binding pocket in GPCRs. Nature, 535(7610), 182-186.
Full text: Click here
Publication 2016
Buffers Centrifugation cholesterol-hemisuccinate dodecyl maltoside Freezing HEPES imidazole Magnesium Chloride Sepharose Sodium Chloride Timolol Tissue, Membrane
4
Purification of Timolol-Bound GPCR Receptors
Cited 3 times
Frozen membranes were thawed on ice and NaCl, MgCl2, and GTPγS were added to reach final concentrations of 300 mM, 1 mM, and 10 μM, respectively. Timolol was then added to a final concentration of 1 μM and the membranes were incubated for 10 minutes on ice. Receptors were solubilized for 1 hour at 4 °C in the presence of 1% dodecylmaltoside (DDM) and 0.1% cholesterol hemisuccinate (CHS). Following centrifugation for 30 minutes at 25,000g, the supernatant was applied to Ni-NTA agarose. The column was slowly washed with 20 column volumes of 20 mM HEPES, pH 8.0, 300 mM NaCl, 0.1% DDM, 0.01% CHS to remove bound timolol. Receptor was eluted in the same buffer plus 200 mM imidazole and concentrated using an Amicon 30 kDa-cutoff spin concentrator for addition to the rHDL reconstitution mixture.
DeVree B.T., Mahoney J.P., Vélez-Ruiz G.A., Rasmussen S.G., Kuszak A.J., Edwald E., Fung J.J., Manglik A., Masureel M., Du Y., Matt R.A., Pardon E., Steyaert J., Kobilka B.K, & Sunahara R.K. (2016). Allosteric coupling from G protein to the agonist binding pocket in GPCRs. Nature, 535(7610), 182-186.
Publication 2016
Buffers Centrifugation cholesterol-hemisuccinate dodecyl maltoside Freezing HEPES imidazole Magnesium Chloride Sepharose Sodium Chloride Timolol Tissue, Membrane
5
Differentiation and Aging of hiPSC-Cardiomyocytes
Cited 3 times
All hiPSC-cardiomyocytes were derived from the Gibco® Human Episomal iPSC
Line (Life Technologies, Carlsbad, CA), following a previously reported
protocol.4 (link) HiPSCs were maintained in
chemically defined conditions on plates coated with truncated human vitronectin (VTN-N) in
Essential 8™ medium (Life Technologies). For differentiation, hiPSCs
were plated as colonies at a low density on truncated VTN-N-coated 6-well plates in
Essential 8™ Medium. HiPSCs were grown to 80% confluency at
which point chemically defined directed differentiation was performed in RPMI 1640 medium
supplemented with 213 μg/mL L-Ascorbic Acid (Sigma-Aldrich, St. Louis, MO) and 500
μg/mL human serum albumin (ScienCell, Carlsbad, CA) (CDM3)4 (link) with the sequential application of CHIR 99021 (6
μM, d0–d1) followed by inhibitor of Wnt protein 2 (IWP2, 5 μM,
d3–d5; Thermo Fisher Scientific, Waltham, MA, USA). After two to three weeks of
differentiation, hiPSC-CMs were harvested using 0.25% Trypsin (Life Technologies)
and dispersed into single cells via trituration. HiPSC-cardiomyocytes were replated on
Matrigel-coated, #1.5 glass coverslips at approximately 26,000
cells/cm2. Aged hiPSC-cardiomyocytes were cultured for 12 months before being
trypsinized and replated. Aged cells were cultured for 6 days before staining and imaging
to correspond with replating time of PE-treated cells.
Neonatal rat ventricular myocytes (NRVMs) were a generous gift from Dr. Ulrike
Mende (Cardiovascular Research Center, Rhode Island Hospital) and were harvested in
accordance with all institutional and national guidelines for the care and use of
laboratory animals as approved by the Institutional Animal Care and Use Committee. NRVMs
and hiPSC-cardiomyocytes were given 72 hours to adhere and recover after replating and
before beginning stimulation by phenylephrine (PE). Cells received either PE (2
μM) with Timolol (to ensure α-adrenergic stimulation, 0.2
μM)32 (link) or media alone for 72
hours. For cytosolic volume experiments, hiPSC-cardiomyocytes were incubated with Alexa
Fluor® conjugated wheat germ agglutinin (WGA, 10 μg/mL, Thermo Fisher
Scientific) for 10 minutes prior to fixation. All cells were then rinsed with KCl (100 mM)
to induce diastole and fixed in 4% paraformaldehyde for 10 minutes at 4°C.
Cells were stored in DPBS at 4°C until stained.
Rupert C.E., Chang H.H, & Coulombe K.L. (2016). Hypertrophy Changes 3D Shape of hiPSC-Cardiomyocytes: Implications for Cellular Maturation in Regenerative Medicine. Cellular and Molecular Bioengineering, 10(1), 54-62.
Publication 2016
Adrenergic Agents Animals Ascorbic Acid Cardiovascular System Cells Cellular Senescence Chir 99021 Cytosol Diastole Episomes Heart Ventricle Homo sapiens Human Induced Pluripotent Stem Cells Infant, Newborn Institutional Animal Care and Use Committees Muscle Cells Myocytes, Cardiac paraform Phenylephrine Serum Albumin, Human Timolol Trypsin Vitronectin Wheat Germ Agglutinins Wnt 2 Protein WNT2 protein, human

Most recents protocols related to «Timolol»

1
Long-Term Beta-Blocker Use and Medication Patterns
The use of BBs was identified according to the self-reported prescription medications questionnaire (https://wwwn.cdc.gov/nchs/nhanes/continuousnhanes/questionnaires.aspx?BeginYear=2005). Non-selective BBs included propranolol, carvedilol, nadolol, sotalol, pindolol, labetalol, penbutolol and timolol. Selective BBs included nebivolol, metoprolol, atenolol, bisoprolol, acebutolol, and betaxolol. The duration of the use of BBs was also obtained from the questionnaire, which was divided into four quartiles as follows: First quartile, ≤2 years; second quartile, 2-4 years; third quartile, 4-6 years; fourth quartile, >6 years). The long-term use of BBs in participants was defined as a BB treatment duration of >6 years.
Luo Y., Liu J., Feng W., Lin D., Song G., Chen M, & Zheng H. (2023). Use of β‑blockers and risk of age‑related macular degeneration among hypertensive patients: An insight from The National Health and Nutrition Examination Survey. Medicine International, 3(1), 10.
Full text: Click here
Publication 2023
Acebutolol Atenolol Betaxolol Bisoprolol Carvedilol Labetalol Metoprolol Nadolol Nebivolol Penbutolol Pindolol Prescription Drugs Propranolol Sotalol Timolol
2
Melatonin and Glaucoma: Lowering IOP
Animals were used in agreement with the Association for Research in Vision and Ophthalmology statement for the Use of Animals in Ophthalmic and Vision Research. The study also agrees with the European Communities Council Directive (2010/63/UE) and the Italian guidelines for animal care (DL 26/14). The experimental protocol was approved by the Commission for Animal Wellbeing of the University of Pisa (protocol n. 133/2019-PR). Rats (Sprague Dawley strain, 200 g body weight, 2–3 months of age) were obtained from Charles River Laboratories Italy (Calco, Italy). Before handling for tonometry, rats were acclimatized for 1 week. To evaluate the effects of melatonin (given at 0.5% or 0.2%), 0.2% agomelatine and commercially available drugs commonly used to reduce IOP in glaucoma patients (i.e., 0.5% timolol and 0.2% brimonidine) on normotensive rats, 3 rats (6 eyes, 3 measurements/eye/time point) were used for each formulation. Rats were treated with 10 µL per eye of formulations of melatonin prepared in Soluplus 1 mM (Merck) and borate buffer, pH 7.4. Ten µL per eye of hypotensive drugs were administered as well. The IOP was measured from time 0 (before administration) to 6 h after administration using the TonoLab device (Icare, Finland).
For the hypertensive model, 3 rats (6 eyes, 3 measurements/eye/time point) were used for each formulation. Ocular hypertension was obtained through the injection in the anterior chamber of the rat eye of 15 µL of 2% methylcellulose (MCE), as previously described [78 (link)]. Twenty-four hours after the MCE injection, the rats were utilized to evaluate the effects of 0.5% melatonin or other hypotensive drugs (0.5% timolol and 0.2% brimonidine).
Cantarini M., Rusciano D., Amato R., Canovai A., Cammalleri M., Monte M.D., Minnelli C., Laudadio E., Mobbili G., Giorgini G, & Galeazzi R. (2023). Structural Basis for Agonistic Activity and Selectivity toward Melatonin Receptors hMT1 and hMT2. International Journal of Molecular Sciences, 24(3), 2863.
Full text: Click here
Publication 2023
agomelatine Animals Antihypertensive Agents Body Weight Borates Brimonidine Buffers Chambers, Anterior Glaucoma Medical Devices Melatonin Methylcellulose Ocular Hypertension Patients Pharmaceutical Preparations Rattus norvegicus Rivers soluplus Strains Timolol Tonometry, Ocular Vision
3
DMEK Surgery Protocol for Corneal Transplant
Pre-cut corneal donor tissues for primary DMEK grafts were obtained from the Barcelona Tissue Eye Bank. DMEK surgeries were all performed by a single surgeon (J.G.).The surgical technique for primary DMEK surgery was as previously described by our group10 (link),11 (link). DMEK graft positioning onto the recipient posterior stroma was performed using 20% sulfur hexafluoride (SF6) as tamponade. Subconjunctival dexamethasone 80 mg was administered at the end of the surgery. To ensure graft attachment with the aid of SF 20% bubble, patients were instructed on different positioning regimens in the early postoperative period, as we have previously described10 (link),11 (link).
Postoperative treatment was as we previously described12 (link),13 (link), and consisted of topical tobramycin 0.3% and dexamethasone 0.1% (Tobradex; Alcon Cusi, El Mas Nou, Barcelona, Spain) every 2 h for the first postoperative day, then 6 times daily for one week, then 4 times daily for 4 weeks and then tapering over the following 3 months (reduction in 1 drop every 4 weeks); timolol 0.5% (Cusimolol; Alcon Cusi) eye drops 2 times daily for 12 weeks, with additional ocular hypotensive medications if needed; and dexamethasone 0.05% and chloramphenicol 1% ointment at nighttime (DeIcol; Alcon Cusi) for 6 months. Oral methylprednisolone (Urbason; Sanofi Aventis Pharma SA, Barcelona, Spain) was also prescribed and slowly tapered off for the first 3 weeks: 40 mg/day for 3 days; 20 mg/day for 3 more days; 10 mg/day for 1 week; and 10 mg every 48 h for 1 week. A topical corticosteroid was kept at least once daily indefinitely after DMEK, unless contraindicated in light of significant increases in intraocular pressure.
In patients with vs-CMO after DMEK, first-line treatment consisted of adding a topical non-steroidal anti-inflammatory (NSAID) drug twice daily (either bromfenac 0.9 mg/mL (Yellox, Bausch & Lomb) or nepafenac 0.1 mg/mL (Nevanac, Novartis)) to the topical steroid regime plus oral acetazolamide 250 mg three times per day (plus oral potassium supplementation) until resolution of CMO. In cases of incomplete response to first-line treatment, the second-line treatment consisted of intravitreal injection of corticosteroids.
Moura-Coelho N., Papa-Vettorazzi R., Santiesteban-García I., Dias-Santos A., Manero F., Cunha J.P, & Güell J. (2023). Outcomes of cystoid macular edema following Descemet’s membrane endothelial keratoplasty in a referral center for keratoplasty in Spain: retrospective study. Scientific Reports, 13, 2375.
Full text: Click here
Publication 2023
Acetazolamide Adrenal Cortex Hormones Anti-Inflammatory Agents, Non-Steroidal Antiglaucoma Agents Antihypertensive Agents bromfenac Chloramphenicol Dexamethasone Eye Drops Grafts Keratoplasty Light Methylprednisolone nepafenac Nevanac Ointments Operative Surgical Procedures Patients Pharmaceutical Preparations Potassium Pressures, Intraocular Steroids Surgeons Timolol Tissue Donors Tissues TobraDex Tobramycin Treatment Protocols Urbason Vision
4
Comparative Effectiveness of KDB Goniotomy and Trabectome
This was a retrospective chart review comparing all patients undergoing KDB goniotomy between January 2016 and March 2020 at New York Eye and Ear Infirmary of Mount Sinai and Trabectome between January 2013 and December 2019 at Yale Eye Center, both in combination with cataract surgery. This study was approved by the Mount Sinai Institutional Review Board (IRB) (IRB-20-03241) and the Yale IRB (IRB-2000026321). Patient consent to review medical records was not required by the Mount Sinai IRB and the Yale IRB, as the use or disclosure of patient health information involved no more than a minimal risk to the privacy of individuals. All efforts were made to maintain patient data confidentiality including use of an encrypted local database and an adequate plan to destroy patient identifiers at the earliest opportunity consistent with the conduct of research. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committees and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Data were collected from subjects aged 18 years or older with at least 1 month of follow-up after surgery. All glaucoma subtypes and severities were included, along with patients with history of selective laser trabeculoplasty (SLT) or argon laser trabeculoplasty (ALT). Exclusion criteria included age less than 18 years, having prior intraocular surgery, and having additional glaucoma surgery performed at the time of KDB or Trabectome with cataract surgery or within 12 months of the initial surgery.
Patient demographics and pre-operative characteristics were gathered. Visual acuity was evaluated via Snellen chart, intraocular pressure (IOP) via Goldmann applanation tonometry, visual fields via 24–2 Humphrey visual field, anterior segment via slit-lamp examination, and posterior segment via dilated fundus examination. Medication regimens were determined at the discretion of each surgeon but included the following medications: bimatoprost, brimonidine, brinzolamide, dorzolamide, latanoprost, methazolamide, netarsudil, pilocarpine, tafluprost, timolol, travoprost, and unoprostone. IOP and number of medications were collected from the visits closest to post-operative month 1 (POM1), month 6 (POM6), and month 12 (POM12) following surgery. Complications including hyphema, IOP elevation greater than 10 mmHg above pre-operative value, ciliary body detachment, hypotony, aqueous misdirection, wound leak, and postoperative infection were recorded. Hyphema was defined as either dispersed or layering and was recorded on post-operative day 1 (POD1). All grades of hyphemas including microhyphema were recorded. Anticoagulation use was recorded categorically in patients taking acetylsalicylic acid, clopidogrel, direct oral anticoagulants, or warfarin. Chart documentation was completed by each individual surgeon. The Enhanced Glaucoma Severity Staging system was used to grade severity.13 (link) Success was defined as an IOP <21 mmHg and at least 20% reduction in IOP at POM12.
Fliney G.D., Kim E., Sarwana M., Wong S., Tai T.Y., Liu J., Sarrafpour S., Chadha N, & Teng C.C. (2023). Kahook Dual Blade versus Trabectome (KVT): Comparing Outcomes in Combination with Cataract Surgery. Clinical Ophthalmology (Auckland, N.Z.), 17, 145-154.
Publication 2023
Anticoagulants Argon Ion Lasers Aspirin Bimatoprost Brimonidine brinzolamide Cataract Extraction Ciliary Body Clopidogrel dorzolamide Ethics Committees, Research Glaucoma Goniotomy Homo sapiens Hyphema Infection Latanoprost Methazolamide netarsudil Ocular Hypotension Operative Surgical Procedures Patients Pharmaceutical Preparations Pilocarpine Slit Lamp Examination Surgeons tafluprost Timolol Tonometry, Ocular Trabeculectomy Travoprost Treatment Protocols Visual Acuity Warfarin Wounds
5
Intraocular Pressure Lowering Drugs in Mice
Pups were anesthetized using an intraperitoneal injection of 50 mg/kg pentobarbital sodium. IOP was measured daily at 10 AM using a rebound tonometer (iCare TONOLAB, Vantaa, Finland) from P12 to P17. At P12, as the mice received intravitreal puncture using needles immediately upon returning to the room air at 6 AM, two additional IOP measurements were taken, both before and after the puncture. Six consecutive probe-to-cornea contact measurements were averaged as one record. For lowering IOP, Travatan (0.004% travoprost, Novartis) and Azarga (10 mg/mL Brinzolamide + 5 mg/mL Timolol, Novartis) eye drops were applied to one eye at a dose of 5 µL from P12 to P17 once a day, while 5 µL of PBS eye drops were applied to the other eye as a control in the same pup mouse. IOP was measured before and 2 h after drug administration at P12. Subsequently, IOP was measured daily at 10 AM from P13 to P17.
Yang Z., Ni B., Zhou T., Huang Z., Zhou H., Zhou Y., Lin S., He C, & Liu X. (2023). HIF-1α Reduction by Lowering Intraocular Pressure Alleviated Retinal Neovascularization. Biomolecules, 13(10), 1532.
Full text: Click here
Publication 2023
Azarga brinzolamide Cornea Eye Drops Injections, Intraperitoneal Mice, House Needles Pentobarbital Sodium Punctures Timolol Travatan Travoprost

Top products related to «Timolol»

1
Timolol by Merck Group
Sourced in United States
Timolol is a laboratory product manufactured by Merck Group. It is a beta-adrenergic antagonist, commonly used as a reference standard in pharmaceutical research and development. Timolol is a white crystalline powder with a molecular formula of C13H24N4O3S and a molecular weight of 344.43 g/mol.
2
Xalatan by Pfizer
Sourced in United States, France
Xalatan is a laboratory equipment product manufactured by Pfizer. It is designed to perform specific functions within a laboratory setting. The core function of Xalatan is to facilitate the measurement and analysis of various samples and materials.
3
Alphagan p by Abbvie
Sourced in United States, Ireland
Alphagan-P is a topical ophthalmic solution used to treat elevated intraocular pressure. It contains the active ingredient brimonidine tartrate, which is an alpha-2 adrenergic receptor agonist that reduces aqueous humor production and increases aqueous humor outflow, leading to a reduction in intraocular pressure.
4
Isoproterenol by Merck Group
Sourced in United States, Germany, Japan, United Kingdom, Sao Tome and Principe, Canada, France, Denmark, Italy, Sweden
Isoproterenol is a synthetic catecholamine used as a laboratory reagent. It acts as a non-selective beta-adrenergic agonist, stimulating both beta-1 and beta-2 adrenergic receptors. Isoproterenol is commonly used in research applications to study cardiovascular and respiratory function.
5
Xalatan eye drops 0.005 by Pfizer
Sourced in Japan
Xalatan® eye drops 0.005% is a prescription eye drop medication manufactured by Pfizer. It contains the active ingredient latanoprost, which is a prostaglandin analog. The core function of Xalatan® is to reduce elevated intraocular pressure, which is a key risk factor for glaucoma.
6
Latanoprost by Pfizer
Sourced in Japan
Latanoprost is a synthetic prostaglandin analog used in the treatment of open-angle glaucoma and ocular hypertension. It works by increasing the outflow of aqueous humor from the eye, thereby reducing intraocular pressure.
7
Combigan by Abbvie
Sourced in United States
Combigan is a combination eye drop product containing the active ingredients brimonidine and timolol. It is designed to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
8
Fetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
9
Tobradex by Alcon
Sourced in United States, Belgium, Switzerland, Greece, Spain, Japan, United Kingdom, Egypt
Tobradex is a topical ophthalmic medication that contains a combination of tobramycin, an antibiotic, and dexamethasone, a corticosteroid. It is used to treat various eye conditions that require both antibiotic and anti-inflammatory treatment.
10
Xalacom combination eye drops by Pfizer
Sourced in United States, Japan
Xalacom® is a combination eye drop product containing the active ingredients latanoprost and timolol maleate. It is designed for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

More about "Timolol"

Timolol is a non-selective beta-adrenergic receptor antagonist that has been widely used in the treatment of various conditions, including glaucoma, hypertension, and angina pectoris.
This medication works by blocking the effects of the neurotransmitter norepinephrine, which can help lower intraocular pressure and blood pressure.
Timolol is available in several formulations, such as eye drops, ointments, and oral tablets.
Researchers can optimize their Timolol studies using PubCompare.ai, an AI-driven tool that helps identify the most relevant protocols from scientific literature, preprints, and patents.
This innovative platform allows researchers to easily compare and select the best protocols and products, enhancing the reproducibility and accuracy of their Timolol research.
By streamlining the research process, PubCompare.ai can take Timolol optimization to new heights.
In addition to Timolol, other medications related to this topic include Xalatan (latanoprost), Alphagan-P (brimonidine), Isoproterenol (a beta-adrenergic agonist), Xalatan® eye drops 0.005% (latanoprost), Latanoprost (a prostaglandin analog), Combigan (a combination of brimonidine and timolol), FBS (fetal bovine serum), Tobradex (a combination of tobramycin and dexamethasone), and Xalacom® (a combination of latanoprost and timolol).
By utilizing the insights and tools provided by PubCompare.ai, researchers can optimize their Timolol studies, leading to more reliable and impactful findings in the field of ophthalmology and cardiovascular research.